RU2544163C1 - Therapeutic agent in form of gel for treating herpetic infection manifestations in patients with burns and cold injuries - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: therapeutic agent contains recombinant interferon specified in a group of: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma, metronidazole, fluconazole and/or voriconazole, and a pharmaceutically acceptable base in the following proportions, g per 1 ml of the mixture: recombinant interferon, international units 100-10,000,000; metronidazole 0.00001-0.5; fluconazole and/or voriconazole 0.00001-0.5; pharmaceutically acceptable base - the rest. Besides, the therapeutic agent contains boric acid in an amount of 0.00001-0.5 g and hypromellose in an amount of 0.00001-0.5 g. As a pharmaceutically acceptable base, it contains macrogol 400 or macrogol 1500, or macrogol 4000.

EFFECT: higher efficacy of the compound.

2 cl, 5 ex

Description

A drug in the form of a gel for the treatment of manifestations of herpes infection in patients with burns and frostbite.

The invention relates to medicine, namely to the creation of a medicinal product in the form of a gel for the treatment of manifestations of herpetic infection in patients with burns and frostbite, having antiviral, immunomodulating, anti-inflammatory, antifungal and antimicrobial effects.

Currently, treatment of herpes infection presents significant difficulties in connection with the chronic recurrent course of the disease, the multi-focal nature of the lesions, immunological changes and anxiety-depressive disorders developing in the patient’s body.

Significant difficulties in the treatment of herpes are noted in patients with burns and frostbite, in particular in socially disadvantaged patients. In this case, the initial violations, including a decrease in the body's defenses, a chronic fungal infection, are exacerbated by immunodeficiency, which develops as a result of the pathogenetic mechanisms of the effects of burns or frostbite, the development of mixed infection.

The objective of the invention is to develop tools for the treatment of herpes infection in patients with burns or frostbite.

It is known to treat patients with recurrent genital herpes in the formation of anxiety-depressive disorders, including specific antiviral therapy (RU 2270012 C2, A61K 31/522, 2006)

Known vaginal suppositories for the treatment of vaginal herpes containing recombinant interferon-alpha, metrogil, fluconazole and boric acid (Obstetrics and Gynecology, 2012, No. 3, p. 3).

However, this therapy applies to another category of patients. The inventors did not find in available sources of information a means for treating herpes in patients with burns or frostbite.

The technical result of the invention is the effective treatment of herpes infection, including mixed infection, in patients with burns or frostbite on the background of developed immunodeficiency, including in socially disadvantaged patients, often with initial violations of the body's defenses, in the presence of chronic infection, including fungal infection.

To achieve the technical result, a gel-like drug for the treatment of common herpetic infections in such patients, which has antiviral, immunomodulating, anti-inflammatory antifungal and antimicrobial effects, contains recombinant interferon-alpha and recombinant interferon-beta or recombinant interferon-alpha and recombinant interferon-alpha and recombinant and also contains metronidazole, fluconazole and voriconazole, boric acid and hypromellose in the following ratio to mponentov, in grams per 1 ml:

recombinant interferon, ME 100-10000000 metronidazole 0.00001-0.5 fluconazole and voriconazole 0.00001-0.5 boric acid 0.00001-0.5 hypromellose 0.00001-0.5 pharmaceutically acceptable base rest

As a pharmaceutically acceptable basis, the proposed tool contains macrogol 400, or macrogol 1500, or macrogol 4000.

The present invention is illustrated by specific examples of execution, which, however, are not the only possible, but clearly demonstrate the ability to achieve the desired technical result.

Example 1. To obtain the claimed medicinal product, recombinant interferon-alpha and recombinant interferon-gamma, metronidazole, fluconazole and voriconazole, boric acid and macrogol 400 are mixed as a pharmaceutically acceptable base in the following ratio of components in g per 1 ml of the mixture:

Doses of the components are selected depending on the severity of the clinical situation, the prevalence of infection, the area of burns or frostbite, especially premorbid, concomitant infection.

Example 2. Carried out analogously to example 1. Except that they use instead of recombinant interferon-gamma recombinant interferon-beta, and as a pharmaceutically acceptable base take macrogol 4000.

Example 3. Carried out analogously to example 1. Except that macrogol 1500 is added to the mixture as a polymeric carrier.

Example 4. Patient B., 47 years old, without a fixed place of residence, was admitted to the Moscow City Clinical Hospital No. 18 in Ufa with a diagnosis of a burn of the II-IIIAB-IV degree of the trunk, right lower limb 12% (9%), fungal infection of the nails and Stop. After stabilization and normalization of hemodynamics on the second day, he was transferred for treatment to the SAT-1 fluidizing unit. On the 7th day, during the onset of septicotoxemia of a burn disease, significant immunosuppression was noted, which was characterized by an increased temperature of leukocytosis and an increase in ESR.

Against the background of standard treatment and dressings, the patient began to complain of severe itching, burning, pain in the areas of burns on the trunk and herpetic eruptions on the glans penis. The patient had anxiety and depressive disorders.

When examining the patient, herpetic rashes were revealed in the perineum and penis, as well as on the periphery of burn wounds on the trunk. The rashes were multiple, grouped in shape, small vesicles filled with fluid, prone to fusion, with redness around them. The lesions on the genitals and around the burn wounds on the body were treated with the gel drug of Example 1.

The treatment of rashes was performed twice a day for 5 days. After 2 days, superficial erosion with scanty serous discharge of a yellowish color formed. On the 4th day, crusts appeared, which subsequently disappeared.

After this, staged necrectomy and autodermoplasty with a split mesh flap were performed. After complete epithelization and an early course of rehabilitation, the patient was discharged on the 40th day of treatment.

Example 5. Patient F., 23 years old, was admitted to the Moscow City Clinical Hospital No. 18 in Ufa with a diagnosis of General hypothermia of the I-II degree. Frostbite I-II degree of upper and lower extremities 6%. Received after 8 hours from the moment of injury. A history of drug use, private infectious diseases. In the department, warming was carried out by physical methods, infusion and antibacterial therapy. Normalization of body temperature occurred during the first day in the hospital. On the third day, there was a sharp rise in temperature to 39-40 ° C, weakness, itching in the genital area and in the area of frostbite. Emotionally depressed.

Genital herpes manifested in the form of rashes on the external genitalia, labia minora, in the anus, in the vagina, inside of the thighs and buttocks. Itching and tingling were observed during urination.

The treatment of common herpetic manifestations was carried out by treatment with the gel drug of Example 2.

During the first day, itchy rashes gave way to the appearance of small vesicles with liquid and unclear contents. On the second day, the bubbles were opened, on the third day, the beginning of the healing process was noted, in some of the wounds there was scanty discharge and crusts, which, when using the product, stopped within the next two four days.

The resolution of the infectious viral process occurred in all areas completely on day 5. On the 14th day, the general condition improved, the feeling of anxiety and fear decreased.

Thus, a new therapeutic agent based on available raw materials has been developed, which has high therapeutic activity, exhibits a complex effect on the manifestations of the common herpetic process against the background of a mixed infection in the body. The selected combination of active components allows in unfavorable situations of development of herpetic infection to stop this process, to promote the healing of lesions with a general immunocorrective effect on the body in patients with impaired immunity and a severe course of the disease.

Claims (2)

1. The drug is in the form of a gel for the treatment of manifestations of herpetic infection in patients with burns or frostbite, containing recombinant interferon-alpha and recombinant interferon-beta or recombinant interferon-alpha and recombinant interferon-gamma, metronidazole, fluconazole and Vorozonazole, Vorononazole and Vorozonazole in the following ratio of components, in g per 1 ml of the mixture:
recombinant interferon, ME 100-10000000 metronidazole 0.00001-0.5 fluconazole and voriconazole 0.00001-0.5 boric acid 0.00001-0.5 hypromellose 0.00001-0.5 pharmaceutically acceptable base rest 2. The drug under item 1, characterized in that as a pharmaceutically acceptable base contains macrogol 400, or macrogol 1500, or macrogol 4000.